AGEN — AGENUS INC
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1098972 ·
Last close
$2.96
Market Cap
$123.26M
52W High
$5.08
52W Low
$2.86
ADV30
719,837
Next earnings
2026-08-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 33,736,000 | 21,914,000 | 15,054,000 | 39,226,000 | 186,456,000 | 34,996,000 | 414,439,000 |
| Dec 2025 | 34,204,000 | 26,693,000 | 14,398,000 | -10,578,000 | 226,798,000 | 2,998,000 | 504,659,000 |
| Sep 2025 | 30,235,000 | 5,997,000 | -4,863,000 | 63,914,000 | 233,891,000 | 3,458,000 | 514,759,000 |
| Jun 2025 | 25,691,000 | -1,262,000 | -16,780,000 | -27,955,000 | 185,221,000 | 9,534,000 | 521,529,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-87,527,000
Investing CF
$70,089,000
Financing CF
$32,006,000
CapEx
$-86,000
Dividends Paid
—
Buybacks
$-92,000
EPS Diluted TTM
$0.93
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,182,765,000
Inventory
—
Receivables
$7,010,000
ST Investments
—
EBIT TTM
$52,190,000
Pretax Income TTM
$-3,083,000
Interest Exp TTM
$55,273,000
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$123,866,000
EBITDA
$15,188,000
Free Cash Flow
$-53,024,876
Enterprise Value
$123,410,448
Total Cash
$34,996,000
Total Debt
$41,074,000
Shares Out
41,642,431
Trailing EPS
$2.05
Book Value
$-5.74
ROE
—
ROA
2.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 114,196,000 | -20,556,000 | 115,000 | 226,798,000 | 504,659,000 | — | -77,195,000 |
| Dec 2024 | 103,463,000 | -124,429,000 | -227,212,000 | 226,271,000 | 532,695,000 | — | -158,315,000 |
| Dec 2023 | 156,314,000 | -160,105,000 | -245,761,000 | 313,913,000 | 462,295,000 | — | -224,202,000 |
| Dec 2022 | 98,024,000 | -180,242,000 | -220,074,000 | 413,556,000 | 468,458,000 | — | -175,373,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.30
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $3.00 · spot: $2.96 · call volume: 313 · put volume: 33
Expected Move to 2027-01-15:
±$1.77
(59.80%) —
implied range
$1.19 –
$4.73
· ATM straddle on $3.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CRDL | Cardiol Therapeutics Inc. | $122.19M | $1.06 | — |
| CGTX | COGNITION THERAPEUTICS INC | $127.09M | $1.42 | — |
| ENGN | enGene Therapeutics Inc. | $116.56M | $1.74 | — |
| VXRT | Vaxart, Inc. | $137.97M | $0.57 | — |
| KLRS | Kalaris Therapeutics, Inc. | $108.25M | $4.55 | — |
News headlines (Yahoo Finance, 1h cache)
Agenus Annual Meeting: BOT/BAL Leads Cancer Drug Push as Balance Sheet Improves
2026-06-16 16:06 · Yahoo
Why Is Agenus (AGEN) Down 9.6% Since Last Earnings Report?
2026-06-10 15:30 · Yahoo
AGEN Early Access Revenues Signal a New Path Ahead of Approval
2026-06-05 18:01 · Yahoo
Is Agenus Stock a Hold Amid Valuation and Funding Risks?
2026-06-05 17:59 · Yahoo
AGEN BOT+BAL: What the BATTMAN Trial Means for mCRC
2026-06-05 17:54 · Yahoo
Agenus Announces Virtual 2026 Annual Shareholders Meeting
2026-06-02 20:30 · Yahoo
IBRX Stock Outlook After Q1 Results and a New FDA Review
2026-05-29 17:25 · Yahoo
ImmunityBio: Anktiva Explained and What Comes Next
2026-05-29 17:21 · Yahoo
AGEN vs. IOVA: Which Cancer Biotech Stock Has More Upside Potential?
2026-05-28 14:49 · Yahoo
How Agenus' Pipeline Progress Unlock Its Next Growth Phase
2026-05-26 16:31 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.